, Singapore
322 views
Logo from Thomson Medical

Thomson Medical issues $155m notes at 5.25%

These will be listed on the SGX on 14 May 2024.

Thomson Medical Group Limited announced that it has issued $155m worth of notes due in 2027 with 5.25% interest annually.

According to a bourse filing, the company said the series 004 notes were issued pursuant to the $1b Multicurrency Debt Issuance Programme established on 28 June 2019 and updated on 21 April 2023.

DBS Bank Ltd. has been tapped as the sole global coordinator and DBS Bank Ltd., Maybank Securities Pte. Ltd., Oversea-Chinese Banking Corporation Limited, UBS AG Singapore Branch and United Overseas Bank Limited have been appointed as the joint lead managers and joint bookrunners.

“Approval in-principle has been received from the Singapore Exchange Securities Trading Limited for the listing and quotation of the Series 004 Notes on the SGX-ST,” Thomson Medical said. 

Earlier, Thomson Medical announced that it will issue $140m worth of notes, which was later on increased by $15m.

The company has said that proceeds from the issuance will be used for refinancing of existing borrowings and general working capital of the group.

Join Singapore Business Review community

Follow the link for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.